Free tool
FAERS Monitor: Cibinqo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213871 or its brand name (Cibinqo, Abrocitinib). Reports on generic versions are filed under their own applications.
Reports
3,948
Serious
1,377
35% of reports
Hospitalization
412
Death reported
70
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective537
- condition aggravated366
- off label use323
- pruritus247
- therapeutic product effect incomplete208
- rash184
- dermatitis atopic179
- nausea166
- headache109
- eczema95
- acne89
- fatigue83
- dizziness69
- erythema64
- skin exfoliation62
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 11 |
| 2022 | 416 |
| 2023 | 1,084 |
| 2024 | 1,189 |
| 2025 | 967 |
| 2026 | 277 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,211 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dermatitis atopicSignal | 179 | 18.1 | 15.7 | 2,880 |
| therapeutic product effect incompleteSignal | 208 | 15.6 | 13.7 | 2,833 |
| eczemaSignal | 95 | 9.7 | 7.9 | 732 |
| condition aggravatedSignal | 366 | 6.4 | 5.8 | 1,692 |
| acneSignal | 89 | 6.3 | 5.1 | 389 |
| skin exfoliationSignal | 62 | 3.9 | 3.1 | 132 |
| pruritusSignal | 247 | 3.4 | 3.0 | 429 |
| rashSignal | 184 | 2.2 | 2.0 | 129 |
| drug ineffectiveSignal | 537 | 2.2 | 2.0 | 361 |
| off label use | 323 | 2.0 | 1.8 | 159 |
| erythema | 64 | 1.7 | 1.3 | 16 |
| nausea | 166 | 1.1 | 1.0 | 2 |
| headache | 109 | 0.9 | 0.8 | 1 |
| dizziness | 69 | 0.7 | 0.6 | 6 |
| fatigue | 83 | 0.6 | 0.5 | 28 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.